Subjects with Established Lyme disease diagnosis  Inclusion Criteria:  Subjects with confirmed early localized or disseminated Lyme Borreliosis manifestation. The EM rash has been present < 6 weeks and the clinical diagnosis has been confirmed by the practitioner. Detailed description of the EM rash with consent for photographic documentation will be requested. Ability to provide the minimum sample volume required.  Subjects with signs and symptoms consistent with suspicion of acute or recent Borreliosis, e.g. fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes  Inclusion Criteria:  Subjects with known or suspected tick bite within 8 weeks of medical examination Absence of EM rash. Diagnostic test result(s) for Lyme disease available (Practitioner diagnosis is based on the data from standard clinical practice). Ability to provide the minimum sample volume required.  Exclusion Criteria:  Subjects unable to provide informed consent. Subjects without clinical information and/or not meeting inclusion criteria. Subjects having started antibiotic treatment > 7 days before inclusion. Subjects having ongoing signs or symptoms attributed to a previous episode of Lyme borreliosis.  Healthy Subjects  Inclusion Criteria:  Apparently healthy subjects with no present fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes, e.g. flu-like symptoms. Ability to provide the minimum sample volume required.  Exclusion Criteria:  Subjects unable to provide informed consent. Subjects without clinical information and/or not meeting inclusion criteria. Subjects with a past or recent diagnosis of Lyme disease, Anaplasmosis, Babesiosis, or history of known embedded tick bite which may have required 'manual extraction'.  Subjects having started antibiotic treatment > 7 days before inclusion.  Uncontrolled HIV-infection, if known. Active syphilis or leptospirosis, if known. Active infection with Epstein Barr Virus (mononucleosis), if known. Active infection with Cytomegalovirus (CMV), if known. Subjects with autoimmune diseases, either confirmed rheumatoid arthritis or other autoimmune disorders diagnosed according to the leading guidelines. Current immunomodulation mediation including >7.5 mg prednisone daily, methotrexate, biologicals. Medications such as hydroxychloroquine, sulfasalazine or NSAIDs are acceptable. Immunodeficiency, hematologic malignancies in the medical history. Chemotherapy during the past year.